Clinical Trials
5
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
4
80.0%
Unknown
1
20.0%
No approval data available
- Google Research's SensorFM, trained on over one trillion minutes of wearable sensor data from five million people, predicts 35 health outcomes including cardiovascular risk, depression, and anxiety from consumer smartwatch signals. - In a blinded physician evaluation, AI-generated health summaries grounded in SensorFM predictions were statistically indistinguishable from summaries built on actual clinical ground-truth measurements. - The model's scaling experiments show no performance saturation across four orders of magnitude in data and model size, suggesting entities with larger consented biometric datasets hold a compounding structural advantage. - SensorFM employs Adaptive and Inherited Masking (AIM) to learn from fragmented real-world sensor data, improving random imputation by 74.8% and sensor signal imputation by 83.7% over baselines.
- Liom announced a CHF 13 million Series A extension, bringing total Series A funding to CHF 38 million with participation from Red Bull Ventures and other notable investors. - The company achieved a breakthrough in miniaturizing its Raman spectroscopy platform, outperforming table-sized lab devices by 12x while enabling smartwatch sizing and >24-hour battery life. - Clinical results published in January 2025 demonstrated a 14.5% MARD without calibration in over 130 subjects, matching first-generation CGM performance levels. - The world's first calibration-free, non-invasive glucose monitoring wearable is expected to launch in 2028, targeting both consumer and athletic markets.
- Northwestern University researchers have developed a new health metric that divides average daily heart rate by step count, providing a more reliable measure of cardiovascular fitness than either measurement alone. - The study analyzed data from nearly 7,000 adults, finding that people with higher heart rate per step ratios were twice as likely to have type 2 diabetes and 1.7 times more likely to have heart failure. - Smartwatch-based exercise programs have also shown promise for diabetes management, with participants 10 times more likely to start exercise regimens and three times more likely to maintain them after one year.
- Digital health technologies and wearables offer a solution to the challenges of rare disease clinical trials by providing continuous real-world data instead of limited clinic visit snapshots. - The orphan drug sector, projected to reach $176 billion by 2020, faces significant hurdles with 42% of pediatric trials failing and 37% of EU-approved orphan drugs rejected at health technology assessment stages. - Patient-centric digital solutions can create more inclusive research processes, connect isolated rare disease communities globally, and potentially increase treatment adherence while reducing barriers to specialized care.
- Apple has introduced its Research app in the US, enabling iPhone and Watch users to participate in studies on women's health, cardiovascular conditions, and hearing impacts, with leading research institutions. - The women's health study, partnering with Harvard University and NIEHS, will investigate connections between menstrual cycles and conditions like PCOS, while the heart study with Brigham and Women's Hospital will monitor for AFib and heart disease. - The app emphasizes data privacy and user control, allowing participants to manage their data sharing preferences while contributing to multiple studies simultaneously through a unified platform.
